Drug Ther Bull. 2015 Dec;53(12):138-40. doi: 10.1136/dtb.2015.12.0369.
▼Naloxegol (Moventig-AstraZeneca) is a peripherally acting mu-opioid receptor antagonist licensed for the treatment of opioid-induced constipation in adults who have had an inadequate response to laxative treatment. It was launched in the United Kingdom in October 2015. Here, we review the evidence for naloxegol and consider its place in the management of opioid-induced constipation.
▼纳洛西醇（商品名：Moventig，阿斯利康公司生产）是一种外周作用的μ-阿片受体拮抗剂，已获许可用于治疗对泻药治疗反应不佳的成人阿片类药物所致便秘。它于2015年10月在英国上市。在此，我们回顾纳洛西醇的相关证据，并探讨其在阿片类药物所致便秘管理中的地位。
